JP2020521445A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020521445A5 JP2020521445A5 JP2019564464A JP2019564464A JP2020521445A5 JP 2020521445 A5 JP2020521445 A5 JP 2020521445A5 JP 2019564464 A JP2019564464 A JP 2019564464A JP 2019564464 A JP2019564464 A JP 2019564464A JP 2020521445 A5 JP2020521445 A5 JP 2020521445A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- peptide
- pharmaceutical composition
- composition according
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 claims description 26
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 208000035473 Communicable disease Diseases 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000035475 disorder Diseases 0.000 claims description 9
- 230000003463 hyperproliferative effect Effects 0.000 claims description 9
- 206010040047 Sepsis Diseases 0.000 claims description 7
- 231100000444 skin lesion Toxicity 0.000 claims description 7
- 206010040882 skin lesion Diseases 0.000 claims description 7
- 230000002087 whitening effect Effects 0.000 claims description 7
- 101000755953 Bacillus subtilis (strain 168) Ribosome maturation factor RimP Proteins 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 239000003112 inhibitor Substances 0.000 claims description 6
- 244000309459 oncolytic virus Species 0.000 claims description 6
- 102220277134 rs776745497 Human genes 0.000 claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 210000004027 cell Anatomy 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 5
- 102100033793 ALK tyrosine kinase receptor Human genes 0.000 claims description 4
- 101710168331 ALK tyrosine kinase receptor Proteins 0.000 claims description 4
- 101150051188 Adora2a gene Proteins 0.000 claims description 4
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 4
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 4
- 102000003964 Histone deacetylase Human genes 0.000 claims description 4
- 108090000353 Histone deacetylase Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 108060003951 Immunoglobulin Proteins 0.000 claims description 4
- 102000053646 Inducible T-Cell Co-Stimulator Human genes 0.000 claims description 4
- 108700013161 Inducible T-Cell Co-Stimulator Proteins 0.000 claims description 4
- 102000002698 KIR Receptors Human genes 0.000 claims description 4
- 108010043610 KIR Receptors Proteins 0.000 claims description 4
- 102100020862 Lymphocyte activation gene 3 protein Human genes 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 239000000556 agonist Substances 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- 102000018358 immunoglobulin Human genes 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000006467 substitution reaction Methods 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 3
- 230000006044 T cell activation Effects 0.000 claims description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- YIMATHOGWXZHFX-WCTZXXKLSA-N (2r,3r,4r,5r)-5-(hydroxymethyl)-3-(2-methoxyethoxy)oxolane-2,4-diol Chemical compound COCCO[C@H]1[C@H](O)O[C@H](CO)[C@H]1O YIMATHOGWXZHFX-WCTZXXKLSA-N 0.000 claims description 2
- TXQAZWIBPGKHOX-UHFFFAOYSA-N 1H-indol-3-amine Chemical compound C1=CC=C2C(N)=CNC2=C1 TXQAZWIBPGKHOX-UHFFFAOYSA-N 0.000 claims description 2
- 101710144268 B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101150013553 CD40 gene Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 150000008574 D-amino acids Chemical class 0.000 claims description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 claims description 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 2
- 101000801234 Homo sapiens Tumor necrosis factor receptor superfamily member 18 Proteins 0.000 claims description 2
- 150000008575 L-amino acids Chemical class 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 claims description 2
- 229920002807 Thiomer Polymers 0.000 claims description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 2
- 102100033728 Tumor necrosis factor receptor superfamily member 18 Human genes 0.000 claims description 2
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 2
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims description 2
- 108091008605 VEGF receptors Proteins 0.000 claims description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 2
- 230000021736 acetylation Effects 0.000 claims description 2
- 238000006640 acetylation reaction Methods 0.000 claims description 2
- 239000002998 adhesive polymer Substances 0.000 claims description 2
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000903 blocking effect Effects 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 238000009566 cancer vaccine Methods 0.000 claims description 2
- 229940022399 cancer vaccine Drugs 0.000 claims description 2
- 238000002659 cell therapy Methods 0.000 claims description 2
- 239000002299 complementary DNA Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 239000003862 glucocorticoid Substances 0.000 claims description 2
- 208000002672 hepatitis B Diseases 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000002502 liposome Substances 0.000 claims description 2
- 201000004792 malaria Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 239000011859 microparticle Substances 0.000 claims description 2
- 239000007908 nanoemulsion Substances 0.000 claims description 2
- 239000002105 nanoparticle Substances 0.000 claims description 2
- 239000002773 nucleotide Substances 0.000 claims description 2
- 125000003729 nucleotide group Chemical group 0.000 claims description 2
- 101710135378 pH 6 antigen Proteins 0.000 claims description 2
- LQRJAEQXMSMEDP-XCHBZYMASA-N peptide a Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)NCCCC[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C/C=1C=CC=CC=1)C(N)=O)C(=O)C(\NC(=O)[C@@H](CCCCN)NC(=O)CNC(C)=O)=C\C1=CC=CC=C1 LQRJAEQXMSMEDP-XCHBZYMASA-N 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 239000002047 solid lipid nanoparticle Substances 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 2
- 102000003390 tumor necrosis factor Human genes 0.000 claims description 2
- 229960005486 vaccine Drugs 0.000 claims description 2
- 239000012646 vaccine adjuvant Substances 0.000 claims description 2
- 229940124931 vaccine adjuvant Drugs 0.000 claims description 2
- 102100023990 60S ribosomal protein L17 Human genes 0.000 claims 1
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762510900P | 2017-05-25 | 2017-05-25 | |
| US62/510,900 | 2017-05-25 | ||
| PCT/US2018/034625 WO2018218137A1 (en) | 2017-05-25 | 2018-05-25 | Pd-1 and ctla-4 dual inhibitor peptides |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020521445A JP2020521445A (ja) | 2020-07-27 |
| JP2020521445A5 true JP2020521445A5 (enExample) | 2021-05-13 |
| JP7187486B2 JP7187486B2 (ja) | 2022-12-12 |
Family
ID=62705685
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019564464A Active JP7187486B2 (ja) | 2017-05-25 | 2018-05-25 | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11033622B2 (enExample) |
| EP (1) | EP3630807B1 (enExample) |
| JP (1) | JP7187486B2 (enExample) |
| AU (1) | AU2018273958B2 (enExample) |
| CA (1) | CA3064023A1 (enExample) |
| ES (1) | ES3041991T3 (enExample) |
| WO (1) | WO2018218137A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| CA3124524A1 (en) * | 2019-01-04 | 2020-07-09 | Oncorus, Inc. | Encapsulated rna polynucleotides and methods of use |
| US20200383961A1 (en) * | 2019-06-06 | 2020-12-10 | Huya Bioscience International, Llc | Triplet therapies of hdac inhibitors, pd-l1 and/or pd-1 inhibitors, and ctla-4 inhibitors |
| WO2021247789A1 (en) * | 2020-06-04 | 2021-12-09 | Leidos, Inc. | Immunomodulatory compounds |
| JP2023548662A (ja) * | 2020-10-12 | 2023-11-20 | レイドス， インコーポレイテッド | 免疫調節性ペプチド |
| CN112745384A (zh) * | 2021-01-15 | 2021-05-04 | 新乡学院 | 猪pd-l14qn-gf表位多肽及其应用 |
| BR112023015467A2 (pt) | 2021-02-02 | 2023-10-10 | Geovax Inc | Vetor viral de vaccinia ankara recombinante modificado, métodos para aumentar uma resposta imunológica a um antígeno alvo em um paciente e para prevenir, tratar ou induzir uma resposta imunológica contra um antígeno alvo, e, composição farmacêutica |
| CN112724197A (zh) * | 2021-02-03 | 2021-04-30 | 河南大学 | 一种免疫治疗中用于阻断pdl1的7肽 |
| KR20230158044A (ko) * | 2021-03-18 | 2023-11-17 | 남미 테라퓨틱스, 인크. | 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법 |
| CN116262137A (zh) * | 2021-12-14 | 2023-06-16 | 四川大学 | 一种同时杀伤肿瘤和改善免疫微环境的抗肿瘤联合用药物 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0909324A2 (en) * | 1996-07-01 | 1999-04-21 | Mycogen Corporation | Toxins active against pests |
| EP0970128A1 (en) | 1997-03-21 | 2000-01-12 | Brigham And Women's Hospital | Immunotherapeutic ctla-4 binding peptides |
| PL345241A1 (en) | 1998-05-06 | 2001-12-03 | Upjohn Co | Introduction of naked dna or rna encoding non-human vertebrate peptide hormones or cytokines into a non-human vertebrate |
| JP2008500013A (ja) | 2003-10-03 | 2008-01-10 | ザ ブライハム アンド ウイメンズ ホスピタル，インコーポレイテッド | Ｔｉｍ−３ポリペプチド |
| US10668119B2 (en) | 2005-08-01 | 2020-06-02 | Virocure, Inc. | Attenuated reovirus |
| JP5368450B2 (ja) | 2007-09-21 | 2013-12-18 | カディラ・ヘルスケア・リミテッド | ペプチドの高発現に適した融合タンパク質システム |
| US20130202623A1 (en) | 2010-02-16 | 2013-08-08 | Nicolas Chomont | Pd-1 modulation and uses thereof for modulating hiv replication |
| MX2012009632A (es) * | 2010-02-18 | 2012-09-28 | Athenix Corp | Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, axmi225z y metodos para su uso. |
| CN103119054B (zh) | 2010-03-26 | 2017-01-18 | 达特茅斯大学理事会 | Vista调节性t细胞介体蛋白、vista结合剂及其用途 |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
| WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
| CN102085735B (zh) | 2010-11-09 | 2013-03-27 | 浙江大东南包装股份有限公司 | 一种多功能bopp烟用包装膜及其制造方法 |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| WO2012116714A1 (en) | 2011-03-02 | 2012-09-07 | Curevac Gmbh | Vaccination in elderly patients |
| EP2717895A1 (en) | 2011-06-08 | 2014-04-16 | Aurigene Discovery Technologies Limited | Therapeutic compounds for immunomodulation |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| EP2583975A1 (en) | 2011-10-21 | 2013-04-24 | Heinrich-Heine-Universität Düsseldorf | Agents and methods for the expression and secretion of peptides and proteins |
| WO2013132317A1 (en) | 2012-03-07 | 2013-09-12 | Aurigene Discovery Technologies Limited | Peptidomimetic compounds as immunomodulators |
| CN104245726A (zh) | 2012-03-29 | 2014-12-24 | 奥瑞基尼探索技术有限公司 | 来自人pd1的bc环的免疫调节环状化合物 |
| CA2884704C (en) | 2012-09-07 | 2023-04-04 | Randolph J. Noelle | Vista modulators for diagnosis and treatment of cancer |
| US20150250837A1 (en) | 2012-09-20 | 2015-09-10 | Morningside Technology Ventures Ltd. | Oncolytic virus encoding pd-1 binding agents and uses of the same |
| BR112015007184A2 (pt) | 2012-10-02 | 2017-08-08 | Bristol Myers Squibb Co | combinação de anticorpos anti-kir e anticorpos anti-pd-1 para tratar câncer |
| SG11201506052PA (en) | 2013-02-22 | 2015-09-29 | Curevac Gmbh | Combination of vaccination and inhibition of the pd-1 pathway |
| US9295647B2 (en) | 2013-03-13 | 2016-03-29 | Transdermal Biotechnology, Inc. | Systems and methods for delivery of peptides |
| US9320706B2 (en) | 2013-03-13 | 2016-04-26 | Transdermal Biotechnology, Inc. | Immune modulation using peptides and other compositions |
| EP2792686A1 (en) | 2013-04-17 | 2014-10-22 | Heinrich-Heine-Universität Düsseldorf | Methods for the expression of peptides and proteins |
| WO2014209804A1 (en) | 2013-06-24 | 2014-12-31 | Biomed Valley Discoveries, Inc. | Bispecific antibodies |
| SG10201801428RA (en) * | 2013-08-21 | 2018-03-28 | Curevac Ag | Method for increasing expression of rna-encoded proteins |
| CN104072615B (zh) | 2014-01-26 | 2016-08-24 | 中国人民解放军军事医学科学院基础医学研究所 | 一种能阻断Tim-3信号通路的人Tim-3融合蛋白 |
| PL3099717T3 (pl) | 2014-01-31 | 2019-10-31 | Novartis Ag | Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie |
| PH12020550847A1 (en) | 2014-02-04 | 2022-05-11 | Incyte Corp | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
| US10899840B2 (en) | 2014-02-04 | 2021-01-26 | Pfizer Inc. | Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer |
| BR102014014502B1 (pt) | 2014-06-13 | 2020-09-15 | Ouro Fino Saúde Animal Ltda | Vetor de expressão |
| DK3552615T3 (da) | 2014-07-16 | 2022-02-14 | Transgene | Onkolytisk virus til ekspression af immun-checkpoint-modulatorer |
| ES2833425T3 (es) | 2014-07-16 | 2021-06-15 | Roussy Inst Gustave | Combinación de virus oncolítico con moduladores de punto de control inmunitario |
| US10695426B2 (en) | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| EP3206703B1 (en) | 2014-10-14 | 2021-05-19 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Peptide for treating pancreatic cancer |
| GB201504502D0 (en) | 2015-03-17 | 2015-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against pancreatic cancer and other cancers |
| WO2017023753A1 (en) * | 2015-07-31 | 2017-02-09 | University Of Florida Research Foundation, Inc. | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| US9957325B2 (en) | 2015-10-13 | 2018-05-01 | Formurex, Inc. | Synthetic antibody mimic peptides |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3478321A4 (en) | 2016-06-30 | 2020-04-22 | Oncorus, Inc. | PSEUDOTYPIZED ONCOLYTIC VIRAL ADMINISTRATION OF THERAPEUTIC POLYPEPTIDES |
| US10799555B2 (en) | 2016-09-15 | 2020-10-13 | Leidos, Inc. | PD-1 peptide inhibitors |
| DK3512536T3 (da) | 2016-09-15 | 2020-11-23 | Leidos Inc | Pd-1-peptidinhibitorer |
| EP3630807B1 (en) | 2017-05-25 | 2025-08-13 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
| CN107383174B (zh) | 2017-08-21 | 2019-01-18 | 生工生物工程（上海）股份有限公司 | 一种能与pd-1特异性结合的肿瘤抑制肽及其用途 |
-
2018
- 2018-05-25 EP EP18733407.3A patent/EP3630807B1/en active Active
- 2018-05-25 CA CA3064023A patent/CA3064023A1/en active Pending
- 2018-05-25 US US15/989,750 patent/US11033622B2/en active Active
- 2018-05-25 AU AU2018273958A patent/AU2018273958B2/en active Active
- 2018-05-25 JP JP2019564464A patent/JP7187486B2/ja active Active
- 2018-05-25 WO PCT/US2018/034625 patent/WO2018218137A1/en not_active Ceased
- 2018-05-25 ES ES18733407T patent/ES3041991T3/es active Active
-
2021
- 2021-05-12 US US17/317,985 patent/US12370258B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinsen et al. | The use of toll-like receptor agonists in HIV-1 cure strategies | |
| JP7187486B2 (ja) | Ｐｄ－１およびｃｔｌａ－４二重インヒビターペプチド | |
| JP7284718B2 (ja) | Ｔ細胞の機能を調節するためのアンチセンスオリゴヌクレオチド | |
| US11186825B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting POU2AF1 | |
| US11180730B2 (en) | Compositions and methods for evaluating and modulating immune responses by detecting and targeting GATA3 | |
| EP3368689B1 (en) | Composition for modulating immune responses by use of immune cell gene signature | |
| JP2022533711A5 (enExample) | ||
| JP2021523110A (ja) | 遺伝子発現のためのナノ粒子及びその使用 | |
| ES2955408T3 (es) | Nucleasas modificadas genéticamente optimizadas que tienen especificidad para el gen de la región constante alfa del receptor de linfocitos t humanos | |
| US20190255107A1 (en) | Modulation of novel immune checkpoint targets | |
| US20190262399A1 (en) | Compositions and methods for evaluating and modulating immune responses | |
| US11931409B2 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| US12195746B2 (en) | Compositions and processes for targeted delivery, expression and modulation of coding ribonucleic acids in tissue | |
| CN109121413A (zh) | 使用靶向核酸纳米载体编程治疗性细胞的组合物和方法 | |
| WO2018067991A1 (en) | Modulation of novel immune checkpoint targets | |
| US20200376142A1 (en) | Compositions and methods for organ-protective expression and modulation of coding ribonucleic acids | |
| JP2022190026A (ja) | Ｐｄ－１ペプチド阻害剤 | |
| JP2024544760A (ja) | 細胞及びウイルス受容体相互作用の中断によってａｓｆｖ感染症を遮断する方法 | |
| JP2023536466A5 (enExample) | ||
| JP2023548662A5 (enExample) | ||
| RU2803294C2 (ru) | Композиции и способы органно-защитной экспрессии и модуляции кодирующих рибонуклеиновых кислот | |
| EP4637805A1 (en) | Methods for macrophage polarization | |
| JP2023548662A (ja) | 免疫調節性ペプチド | |
| HK40099663A (en) | Therapeutic rna for treating cancer | |
| CN116615207A (zh) | 经修饰的免疫细胞 |